JUNS Stock Analysis: Buy, Sell, or Hold?
JUNS - Jupiter Neurosciences, Inc. Common Stock
$0.34
0.00 (-1.34%)
▼
5d:
-12.97%
30d:
-11.45%
90d:
-43.38%
HOLD
MODERATE Confidence
Analysis Updated: May 8, 2026 12:00 AM ET
Earnings: May 21, 2026
12d
Get Alerted When JUNS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: JUNS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: JUNS shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
In-depth Analysis How we analyze
Valuation Analysis: JUNS is currently trading at $0.34, which is considered oversold relative to its 30-day fair value range of $0.35 to $0.42. From a valuation perspective, the stock is trading at a discount (Forward PE: 5.7) compared to its historical average (11.1). Remarkably, the market is currently pricing in an annual earnings decline of 19.7% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, JUNS is in a strong downtrend. The price is currently testing key support at $0.34. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: JUNS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $30.00 (+8620.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, JUNS is in a strong downtrend. The price is currently testing key support at $0.34. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: JUNS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $30.00 (+8620.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.35 -
$0.42
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 8620.9% below Wall St target ($30.00)
- CAUTION: 5-day price weakness (-13.0%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.35 -
$0.42
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.34
Resistance Level
$0.42
Current Trend
Strong Downtrend
Technical data as of
May 8, 2026
Fundamental Context
Forward P/E (Next Year Est.)
5.73
Wall Street Target
$30.00
(+8620.9%)
Valuation Discount vs History
-19.7% cheaper
PE vs Historical
5.7 vs 11.1
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-19.7%
(market-implied from PE analysis)
1-Year Target
$0.31
(-10%)
2-Year Target
$0.28
(-19%)
3-Year Target
$0.25
(-27%)
3-Yr Target (if PE normalizes)
(PE: 6→11)
$0.49
(+41%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 5.7 to 11.1
Stabilization Target:
$0.67
(+93.6%)
PE Expansion Potential:
+93.6%
Share & Embed Analysis
Last updated: May 08, 2026 1:55 PM ET
Data refreshes hourly during market hours. Next update: 2:55 PM
Data refreshes hourly during market hours. Next update: 2:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is JUNS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$100 | 69 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$79 | 57 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$93 | 61 BUY |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 58 HOLD |
